Target intelligence / Profile preview

Complement component 1, q subcomponent, B chain (C1QB)

Target
C1QB
Molecular classification
Other (Pattern recognition molecule, part of the complement system), Complement system component, Innate immune system protein
01

Overview

Complement component 1, q subcomponent, B chain (C1QB) is the B-chain polypeptide of the C1q protein, a critical recognition molecule of the classical complement pathway. C1q is composed of 18 polypeptide chains (six each of A, B, and C), forming a bouquet-like hexameric structure with collagen-like stalks and globular head domains. The C1QB subunit contributes specifically to the globular head, which mediates binding to immunoglobulins (such as IgG and IgM), apoptotic cells, and various endogenous and exogenous ligands. Upon binding to its targets, C1q (including C1QB) triggers activation of the serine proteases C1r and C1s, thus initiating the classical pathway of complement activation leading to opsonization, cell lysis, and immune regulation. Beyond complement activation, C1q and its subunits—including C1QB—participate in the clearance of apoptotic cells, modulation of inflammation, angiogenesis, neurodevelopment, and maintenance of tissue homeostasis. Dysregulation and deficiency of C1q are strongly linked to autoimmune diseases (especially lupus), certain neurodegenerative disorders, pregnancy complications, and pathological angiogenesis[1][2][3][4][5].

Other names
Complement C1q subcomponent subunit BC1QBC1QD2Complement C1q chain BComplement component 1, q subcomponent, B chainComplement component 1, q subcomponent, beta polypeptideComplement component C1q, B chainComplement subcomponent C1q chain B
02

Mechanism of action

Inhibition of C1q or C1 complex function to prevent the initiation of the classical complement pathway, aiming to reduce inflammation and tissue damage in autoimmune or inflammatory diseases. Immune modulation by blocking recognition of immune complexes or apoptotic cells.

03

Biological functions

Initiation of the classical pathway of complement activation (by recognizing immune complexes and binding to antibody-antigen complexes)Immune response modulationClearance of apoptotic cellsSynaptic pruning in the central nervous systemAngiogenesis, including pro-angiogenic and wound healing rolesImmune toleranceRegulation of inflammation
04

Disease associations

Autoimmune disease (e.g., lupus erythematosus, glomerulonephritis)InflammationNeurodegenerative disease (involvement in synaptic pruning and microglial interaction)Pregnancy complications (such as preeclampsia and spontaneous loss with C1q deficiency)Cancer (emerging evidence of anti-tumor or pro-tumor roles, particularly via angiogenesis)Infection (protective role against various pathogens through classical complement activation)Cardiovascular complications (angiogenesis, vascular remodeling, aging-related changes)
05

Safety considerations

Increased risk of infection due to suppression of classical complement activation.Potential for impaired clearance of apoptotic cells leading to autoimmunity.Risk of immune dysregulation or impaired immune surveillance for cancer.Possible effects on neurodevelopment and pregnancy outcomes with systemic inhibition, based on C1q’s role in synaptic pruning and placental function.
06

Interacting drugs

No widely approved drugs directly targeting C1QB. There are investigational agents and biologics targeting the classical complement pathway, including C1q or the C1 complex. These include:

2 more in the full profile.

07

Biomarkers

Serum C1q levels (decreased in systemic lupus erythematosus, increased in aging, may change in autoimmune and inflammatory diseases)Complement activity assays (classical pathway activity as a readout of C1q functionality)

Beyond the preview

Go deeper on Complement component 1, q subcomponent, B chain (C1QB).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Complement component 1, q subcomponent, B chain (C1QB).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call